CD19/BCMA‐Targeted Chimeric Antigen Receptor‐T Cell Therapy for Anti‐HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical Study Authors: Haiqiong Zheng, Houli Zhao, Xinyi Zhu, Jingjing Feng, Guoqing Wei, Shi Han, Simao Huang, Jiazhen Cui, Shan Fu, Mingming Zhang, Yanlei Zhang, Jimin Shi, Yi Luo, Alex H Chang, Yongxian Hu, He Huang Published: 2026 ABSTRACT ABSTRACTAntibodies targeting foreign HLA molecules can be detrimental in transplantation. Nonetheless, existing desensitisation methods for anti‐HLA antibodies frequently prove insufficient. We conducted a single‐arm pilot study to evaluate CD19/B cell maturation antigen (BCMA) chimeric antigen receptor T (CAR‐T) cell therapy for desensitising anti‐HLA antibodies prior to transplantation. Seven patients diagnosed with acute leukaemia participated in the study, comprising four individuals with acute myeloid leukaemia (AML) and three with acute B lymphoblastic leukaemia (B‐ALL). Among them, one patient was treated with BCMA CAR‐T cells, while six received CD19 CAR‐T cells. No instances of neurotoxicity or severe cytokine release syndrome (grade ≥ 3) were noted. CAR‐T cell expansion was observed in six patients (86%), with the exception of patient 3. Among the seven patients with pre‐infusion anti‐HLA‐I antibodies, five (71%) showed a decrease in mean fluorescence intensity (MFI), including three (43%) who experienced a reduction greater than 75%. Among the six patients confirmed to exhibit CAR‐T cell expansion in vivo, three presented with donor‐specific anti‐HLA antibodies (DSAs) prior to CAR‐T cell infusion. The median MFI level of DSA declined from 15797.8 (7750.3–21106.0) to 3831.1 (523.3–13197.0) (p < 0.001) in the three patients studied. Two patients with decreased DSA levels after CD19 CAR‐T cell infusion underwent combined desensitisation before haematopoietic stem cell transplantation. This pilot study illustrates the potential safety and efficacy of CD19 and BCMA CAR‐T cells in desensitising anti‐HLA antibodies in patients with AML or B‐ALL. However, only one patient received BCMA CAR‐T cells in our cohort, so further research with an expanded sample size is essential for comprehensively evaluating the safety and efficacy of CD19/BCMA CAR‐T cell therapy for anti‐HLA antibody sensitisation.Keywords: anti‐HLA antibody, BCMA, CAR‐T, CD19, DSA, leukaemia Introduction Antibodies targeting foreign HLA molecules acquired through pregnancy, blood transfusion, or transplantation can be pathogenic factors in organs or during haematopoietic stem cell transplantation (HSCT). Donor‐specific anti‐HLA antibodies (DSAs) can cause allograft rejection [1, 2]. Anti‐HLA antibodies also contribute greatly to platelet transfusion refractoriness [3, 4]. Contemporary desensitisation methods for anti‐HLA antibodies, such as plasma exchange, intravenous immunoglobulin injection and rituximab, frequently prove inadequate [5]. Therefore, effective anti‐HLA antibody elimination remains a significant clinical challenge. In the past decade, chimeric antigen receptor‐T (CAR‐T) cells have been proven to be effective in treating refractory/relapsed B cell malignancies. CD19/B cell maturation antigen (BCMA)‐targeted CAR‐T cells not only kill malignant cells but also eradicate CD19‐positive B cells and BCMA‐positive plasma cells, resulting in hypogammaglobulinaemia [6, 7, 8, 9, 10]. This study offers initial findings regarding the safety and effectiveness of CD19/BCMA‐targeted CAR‐T cell therapy in patients possessing pre‐transplant anti‐HLA antibodies. Method Trial Design and Oversight We conducted a single‐arm pilot clinical study of CD19/BCMA‐targeted CAR‐T cell therapy for pre‐transplant anti‐HLA antibodies desensitisation at the Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine. Patients with acute B lymphoblastic leukaemia (B‐ALL) received CD19 CAR‐T cells. For patients with acute myeloid leukaemia (AML), CD19 CAR‐T cells were selected if pre‐treatment bone marrow CD19‐positive cells exceeded BCMA‐positive cells within CD45‐positive cells; otherwise, BCMA CAR‐T cells were used. The primary objective of this study was to assess the safety and tolerability of CAR‐T cells, and the secondary objective was to assess the preliminary effectiveness of anti‐HLA antibody desensitisation and to characterise the pharmacokinetics of CAR‐T cells. If any DSA mean fluorescence intensity (MFI) value exceeds 5000 at two months following CAR‐T cell infusion, alternate desensitisation methods (such as plasma exchange, intravenous immunoglobulin and rituximab) should be contemplated. The study protocol received approval from the Institutional Review Board of the First Affiliated Hospital, School of Medicine, Zhejiang University, and was registered on Chictr.org.cn (ChiCTR2100049920). All seven participants and their guardians provided written informed consent in accordance with the Declaration of Helsinki. Detection of Anti‐HLA Antibodies Serum samples treated with ethylenediaminetetraacetic acid from all patients were tested for anti‐HLA class I and II antibodies using multiplex bead assays on the Luminex platform (Luminex Corporation, Austin, TX, USA), including LAB screen PRA and mixed screening methods. Semi‐quantitative detection of DSA levels was performed using LAB screen single antigen bead assays (One Lambda; Thermo Fisher Scientific) per the manufacturer's instructions, with results expressed as MFI. Cumulative DSA MFI was calculated by summing the MFI values of all detected DSA at HLA antigen resolution. The DSA level was defined as the sum of each MFI value of each DSA: anti‐HLA class I DSA (anti‐HLA‐A + anti‐HLA‐B + anti‐HLA‐C), anti‐HLA class II DSA (anti‐HLA‐DR, anti‐HLA‐DP and anti‐HLA‐DQ) and total DSA (anti‐HLA class I + anti‐HLA class II). The highest single DSA MFI was calculated using the MFI of the highest detected DSA at HLA antigen resolution. To better evaluate changes in DSA levels over time, a weakly positive serum control was added to each test, obtained from the residual serum of a sensitised patient. A cut‐off of 2000 MFI was used to define positive DSA, while MFI values between 500 and 1000 were considered weakly positive. CAR‐T Cell Manufacturing and Expansion Assessment The protocol for CAR‐T cell generation at our center has been previously described [10, 11]. Briefly, CD3‐positive T cells were isolated from peripheral blood mononuclear cells and transduced with a lentiviral vector encoding a CAR with CD3‐zeta and 4‐1BB domains. CAR‐T cells were then expanded for another 5 additional days until reaching sufficient numbers for infusion. Post‐infusion, serial peripheral blood samples were collected in K2EDTA BD Vacutainer Tubes (BD Biosciences) to assess CAR‐T cell expansion. CAR‐T cell expansion in fresh peripheral blood was determined using flow cytometry based on the proportion of CAR‐positive cells among CD45‐positive CD3‐positive T lymphocytes. Definitions and Evaluations Cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS) were graded according to the ASTCT consensus guidelines [12]. Neutrophil engraftment was defined as achieving an absolute neutrophil count of 0.5 × 109/L or greater for three consecutive days without granulocyte colony‐stimulating factor (G‐CSF) support. Platelet engraftment was defined as a platelet count of 20 × 109/L or greater, without platelet transfusions, for 7 days. Acute graft‐versus‐host disease (aGVHD) was diagnosed and graded using the established 2016 Harris criteria [13]. Patients who survived > 100 days and were not excluded from the aGVHD analysis were analysed for chronic GVHD (cGVHD). cGVHD was evaluated using the 2014 National Institutes of Health consensus criteria [14]. Relapse was defined based on the histological criteria. Other toxicities during and after therapy were assessed according to the National Institutes of Health Common Terminology Criteria for Adverse Events (version 5.0; http://ctep.cancer.gov/). Statistical Analyses The data cut‐off date was September 30, 2024. Variables were tabulated and summarised using medians and ranges. MFI levels of antibodies at baseline and after infusion were determined using the Wilcoxon signed‐rank test. Statistical significance was set at p < 0.05. Statistical analyses were performed using GraphPad Prism 7 software. Results Patient Characteristics Between March 2020 and April 2021, seven patients with positive pre‐transplant anti‐HLA antibodies were enrolled (Table 1). Of these, four had AML, and three had B‐ALL. All four patients with AML remained in complete remission (CR) (three minimal residual disease [MRD]‐negative CR and one MRD‐positive CR) before CAR‐T cell infusion. Among the three patients with B‐ALL, patient 4 did not achieve remission, with 64% blast cells in the bone marrow, while patients 2 and 7 remained in MRD‐positive CR before CAR‐T cell infusion. All seven patients had anti‐HLA‐I antibodies with a median MFI of 9440.77 (5424.71–21010.2), while patients 2, 3 and 6 also had anti‐HLA‐II antibodies. Patients 1, 3, 4 and 6 had DSAs with a median MFI of 16001.81 (7750.28–21106.02). Seven patients received fludarabine‐based lymphodepletion chemotherapy followed by CAR‐T cell infusion (day 0). Patient 1 received BCMA CAR‐T cells, while patients 2–7 received CD19 CAR‐T cells (Table 1). TABLE 1Baseline clinical characteristics of CAR‐T cell recipients.Patient no.GenderAge (year)DiseaseMolecular abnormalitiesTimes of relapsesLines of previous therapiesBlast cell in BMLevels of anti‐HLA antibodies (MFI)DSAs locusLevels of DSAs (MFI)CAR‐T targetConditioning regimenCAR‐T dose (106/kg)1Female49AMLDNMT3A, FLT3‐ITD, NPM1, WT101MRD−CR HLA‐I: 5424.71 HLA‐II: negative B*58:01 C*03:02 16460.07 7750.28 BCMAFlu 30 mg/m2 d1–3, CTX 0.5 g/m2 d2–3, Ara‐C 150 mg d1–372Female45B‐ALLNF1, ASXL1010.881% HLA‐I: 9440.77 HLA‐II: 3915.4 NegativeNegativeCD19Flu 30 mg/m2 d1–3, CTX 0.5 g/m2 d2–333Female52AMLNPM112MRD−CR HLA‐I: 11092.57 HLA‐II: 8037.95 DQB1*03:02 16001.81CD19Flu 30 mg/m2 d1–3, CTX 0.5 g/m2 d2–324Female61AMLFLT3‐ITD, IDH2, NPM, ATM02MRD−CR HLA‐I: 11483.29 HLA‐II: negative A*02:01 B*40:01 10644.75 15135.49 CD19Flu 30 mg/m2 d1–3, CTX 0.5 g/m2 d1–225Female60B‐ALLBCR/ABL, DNMT3A, KMT2A, ETV61264% HLA‐I: 9255.02 HLA‐II: negative NegativeNegativeCD19Flu 30 mg/m2 d1–3, CTX 0.5 g/m2 d2–326Female48AMLAML/ETO120.016% HLA‐I: 21010.2 HLA‐II: 19325.55 A*24:02 DRB1*12:02 21106.02 19785.18 CD19Ara‐C 100 mg d1–5, Flu 30 mg/m2 d1–327Female58B‐ALLWT1, BCR/ABL140.086% HLA‐I: 7819.46 HLA‐II: negative NegativeNegativeCD19Flu 30 mg/m2 d1–3, CTX 0.5 g/m2 d2–33Abbreviations: AML: acute myeloid leukaemia; Ara‐C: cytarabine; B‐ALL: acute B lymphoblastic leukaemia; BCMA: B cell maturation antigen; BM: bone marrow; CAR‐T: chimeric antigen receptor‐T; CR: complete remission; CTX: cyclophosphamide; DSA: donor‐specific antibody; Flu: fludarabine; MFI: mean fluorescence intensity; MRD: minimal residual disease. Baseline clinical characteristics of CAR‐T cell recipients. HLA‐I: 5424.71 HLA‐II: negative B*58:01 C*03:02 16460.07 7750.28 HLA‐I: 9440.77 HLA‐II: 3915.4 HLA‐I: 11092.57 HLA‐II: 8037.95 HLA‐I: 11483.29 HLA‐II: negative A*02:01 B*40:01 10644.75 15135.49 HLA‐I: 9255.02 HLA‐II: negative HLA‐I: 21010.2 HLA‐II: 19325.55 A*24:02 DRB1*12:02 21106.02 19785.18 HLA‐I: 7819.46 HLA‐II: negative Abbreviations: AML: acute myeloid leukaemia; Ara‐C: cytarabine; B‐ALL: acute B lymphoblastic leukaemia; BCMA: B cell maturation antigen; BM: bone marrow; CAR‐T: chimeric antigen receptor‐T; CR: complete remission; CTX: cyclophosphamide; DSA: donor‐specific antibody; Flu: fludarabine; MFI: mean fluorescence intensity; MRD: minimal residual disease. Adverse Events No ICANS, haemophagocytic lymphohistiocytosis, tumour lysis or capillary leak syndrome occurred during the clinical trial. CRS occurred in four patients (57%) and all were defined as grade 1 with a median onset of 2.5 (1–6) days after infusion and lasted a median of 1.5 (1–3) days. Grade 3 and 4 neutropenia occurred in three (43%) and four (57%) patients, respectively. Six (86%) patients experienced anaemia after CAR‐T cell infusion, with grade 2, 3 and 4 anaemia occurring in three, two and one patient, respectively. Four (57%) patients experienced thrombocytopenia, with one case each of grades 1, 2, 3 and 4. All CRS and haematological toxicities resolved after symptomatic treatment. Patient 2 developed respiratory syncytial virus infection on the 8th day after infusion, which improved after symptomatic treatment. Patient 3 developed gallstones with acute cholecystitis on the first day after infusion, which improved after anti‐infection treatment. On the 21st day after infusion, patient 3 presented with fever and headache and was diagnosed with tuberculous meningitis, which was resolved after 14 months of antituberculosis treatment. CAR‐T Cell Pharmacokinetics and Response Expansion was confirmed by flow cytometry in six of seven patients, except for patient 3. The median time of CAR‐T peak was 11 (9–19) days post‐infusion, and the median duration of CAR‐T was 28 (4–86) days. The median peak of absolute CAR‐T cell count was 838.7 (496.9–1437.1) cells/μL in patients with B‐ALL, while the peak was 46.5 (23.7–719.3) cells/μL in patients with AML (Figure 1A). In the six patients with CAR‐T cell expansion, the median IgG level decreased from 855 (755–1312) mg/dL to 544 (229–875) mg/dL (Figure 1B). We regularly monitored changes in anti‐HLA‐I and anti‐HLA‐II antibody MFI levels after CAR‐T cell infusion. A decrease in MFI levels was observed in five of seven patients with positive anti‐HLA‐I antibodies prior to CAR‐T cell infusion, except in patients 2 and 3. Patients 1, 5 and 7 showed a decrease of > 75% in anti‐HLA‐I antibody MFI levels (Figure 1C). Patients 2, 3 and 6 tested positive for anti‐HLA‐II antibodies at baseline. After CAR‐T cell infusion, the MFI levels of anti‐HLA‐II antibodies decreased in patients 2 and 6, while the MFI level increased in patient 3 (Figure 1D). Among patients with confirmed CAR‐T cell expansion in vivo, the median MFI level of HLA‐I antibodies decreased from 9347.9 (5424.7–21010.2) to 5271.6 (218.6–12179.6), although there was no statistical difference (Figure 1E). Patients 1, 3, 4 and 6 had DSA prior to CAR‐T cell infusion. A reduction in DSA MFI levels was observed in three patients, with the exception of patient 3, who did not demonstrate CAR‐T cell expansion in vivo (Figure 1A,F). Among patients 1, 4 and 6, the median MFI level of DSAs decreased from 15797.8 (7750.3–21106.0) to 3831.1 (523.3–13197.0) (p < 0.001) (Figure 1G). Additionally, all three patients with B‐ALL achieved MRD‐negative CR after CD19 CAR‐T cell infusion. Dynamics of CAR‐T cells in vivo and desensitisation of anti‐HLA antibodies after CAR‐T cell infusion. (A) Flow cytometry analysis showing in vivo dynamics of CAR‐T cells in the peripheral blood of patient 3 (blue) or others (red). (B–D) Longitudinal measurements of IgG (B), anti‐HLA‐I antibody (C), and anti‐HLA‐II antibody (D) in each patient (blue: AML; red: B‐ALL). (E) MFI levels of anti‐HLA‐I antibody before and after CAR‐T cell infusion in patients confirmed with CAR‐T cell expansion in vivo. (F) Longitudinal measurements of DSA in patients 1, 3, 4 and 6. (G) DSA MFI before and after CAR‐T cell infusion in patients 1, 4 and 6. All comparisons were performed using Wilcoxon signed‐rank tests. *p < 0.05. AML: acute myeloid leukaemia; B‐ALL: acute B lymphoblastic leukaemia; CAR‐T: chimeric antigen receptor T; DSA: donor‐specific anti‐HLA antibody; MFI: mean fluorescence intensity. Outcomes of Transplantation Five out of seven patients had allogeneic HSCT (allo‐HSCT) at a median of 125 (89–182) days following CAR‐T cell infusion. Patient 3, who developed tuberculous meningitis after CAR‐T cell infusion, received antituberculosis treatment and azacitidine maintenance therapy instead of HSCT. However, patient 3 relapsed after 15.2 months of CAR‐T cell therapy and was subsequently lost to follow‐up. Patient 7 with Ph‐positive ALL received anti‐CD22 targeted therapy and ponatinib maintenance therapy instead of HSCT, with ongoing leukaemia‐free survival. The characteristics and clinical outcomes of the HSCT recipients are summarised in Table 2. Four of the five patients received haploidentical HSCT, while patient 5 received unrelated 9/10 HLA‐matched HSCT. Patients 4 and 6 received desensitisation before HSCT, whereas the remaining patients did not. Among the five HSCT recipients, patient 1 experienced relapse prior to HSCT, whereas the remaining four patients remained in MRD‐negative CR before HSCT. The median durations to neutrophil engraftment and platelet engraftment among the five HSCT recipients were 12 (10–15) days and 15 (12–18) days, respectively. Patients 1 and 2 experienced grade 1 skin aGVHD after transplantation, and patient 2 developed grade 1 cGVHD involving the eyes and right metacarpophalangeal joint 10.5 months after transplantation. Patient 1 relapsed 11.8 months after transplantation, achieved CR with azacitidine and venetoclax treatments and subsequently underwent unrelated allo‐HSCT. Two months after the second transplantation, patient 1 died of an invasive Rhizopus infection. Patient 4 died 7.5 months after transplantation due to transplant‐associated thrombotic microangiopathy and Enterococcus faecalis sepsis. The remaining 3 patients were leukaemia‐free for more than 3 years after transplantation. TABLE 2Clinical characteristics and outcomes of HSCT recipients.Patient no.Donor relationHLA matchOther desensitisationTime from CAR‐T to transplant (day)Pre‐transplant blast cell in BMTime of neutrophil engraftment (day)Time of platelet engraftment (day)Grade of aGVHD after HSCTGrade of cGVHD after HSCTRelapse after HSCT (month)Survival or death after HSCT (month)1SonHIDNo1498.42%101610Yes (11.8)Death (25.2)2SonHIDNo125MRD−CR111211NoSurvival (41.1)4DaughterHIDPlasma exchange and rituximab89MRD−CR151500NoDeath (7.5)5URD9/10 HLA matchedNo111MRD−CR121400NoSurvival (40.8)6DaughterHIDPlasma exchange, IVIG and rituximab182MRD−CR141800NoSurvival (36.7)Abbreviations: aGVHD: acute graft‐versus‐host disease; BM: bone marrow; CAR‐T: chimeric antigen receptor‐T; cGVHD: chronic graft‐versus‐host disease; CR: complete remission; HID: haploidentical donor; HSCT: haematopoietic stem cell transplantation; IVIG: intravenous immunoglobulin; MRD: minimal residual disease; URD: unrelated donor. Clinical characteristics and outcomes of HSCT recipients. Abbreviations: aGVHD: acute graft‐versus‐host disease; BM: bone marrow; CAR‐T: chimeric antigen receptor‐T; cGVHD: chronic graft‐versus‐host disease; CR: complete remission; HID: haploidentical donor; HSCT: haematopoietic stem cell transplantation; IVIG: intravenous immunoglobulin; MRD: minimal residual disease; URD: unrelated donor. Discussion Recent advancements indicate that CAR‐T cell therapy attains considerable efficacy in both haematological malignancies and autoimmune disorders. CD19 CAR‐T cells, for instance, effectively deplete pathological B cells, reduce pathogenic autoantibodies and enable patients with refractory systemic lupus erythematosus (SLE) to discontinue immunosuppressive agents [15]. Similarly, BCMA CAR‐T cell therapy has shown preliminary success in treating refractory neuromyelitis optica by significantly reducing pathogenic autoantibody levels and alleviating clinical symptoms [16]. HLA antibodies are foreign antibodies produced by an allogeneic antigen contact history, such as pregnancy, blood transfusion and transplantation. CAR‐T cells targeting CD19 or BCMA can substantially deplete secreting B cells or plasma cells that produce these antibodies. However, prior studies suggest that anti‐HLA antibody levels may not consistently decrease after CAR‐T cell treatment. For instance, Hill et al. observed that in four patients with relapsed or refractory B‐NHL treated with CD19 CAR‐T cell therapy, the levels of anti‐HLA antibodies did not show a significant decline [17]. Similarly, Zhang et al. reported the case of a patient with follicular lymphoma treated with CD19 CAR‐T cell therapy, and the patient's anti‐HLA antibodies did not significantly decrease after CAR‐T cell infusion [18]. Subsequently, Zhang et al. reported changes in anti‐HLA antibodies before and after CAR‐T cell therapy in five patients with relapsed or refractory multiple myeloma, among whom three patients received combined BCMA CAR‐T and CD19‐targeted CAR‐T cell therapy and two patients received BCMA CAR‐T cell therapy alone. In the three patients who received combined therapy, anti‐HLA antibodies decreased by 47%–97%. However, in the two patients who received BCMA CAR‐T cell therapy, HLA antibodies did not significantly decrease [19]. Our data examined responses in seven patients positive for HLA antibody treated with CD19 or BCMA CAR‐T cell therapy. The seven cases included four AML cases and three B‐ALL cases. Among the four patients with AML, one received a high‐dose BCMA CAR‐T cell infusion and both anti‐HLA antibodies and DSA significantly decreased, successfully completing without other desensitisation treatments. The three patients with AML and the three patients with B‐ALL all received CD19 CAR‐T cell infusion. Peripheral blood CAR‐T cell monitoring data showed that the expansion of CD19 CAR‐T cells in patients with AML was lower than that in patients with B‐ALL, and one patient with AML failed to achieve CAR‐T cell expansion. This may be because there are fewer CD19‐positive cells in patients with AML (normal B cells) than in those with B‐ALL (normal B cells and leukaemia cells). Therefore, patients with AML may require a higher CAR‐T cell infusion dose for desensitisation to anti‐HLA antibodies. Among the five patients with CAR‐T cell expansion, anti‐HLA‐I antibodies decreased in all but patient 2. Although patient 2's anti‐HLA‐I antibodies did not decrease after CAR‐T cell infusion, anti‐HLA‐II antibodies significantly decreased. In two patients with positive DSA confirmed CAR‐T cell expansion in vivo, DSA levels decreased after CD19 CAR‐T cell infusion. However, the decrease in DSA was not sufficient to safely perform allo‐HCST. These two patients underwent combined desensitisation, including plasma exchange, intravenous immunoglobulin and rituximab before HSCT, meaning that CD19 CAR‐T cell therapy alone may not be sufficiently effective in all sensitised patients. Previous studies have shown that patients receiving BCMA‐targeted CAR‐T cell therapy exhibit lower levels of pathogen‐specific antibodies compared to those treated with CD19‐targeted CAR‐T cell therapy [20, 21, 22]. This difference may be explained by the fact that while CD19 CAR‐T cells can eliminate certain B cells secreting anti‐HLA antibodies, some CD19‐negative long‐lived plasma cells—an important source of anti‐HLA antibodies—may persist [23]. Additionally, both short‐lived and long‐lived plasma cell subsets have been implicated as potential sources of pathogenic anti‐HLA antibodies following transplantation [24]. In contrast, BCMA targets all antibody‐secreting cells, including peripheral short‐lived plasma cells and tissue‐resident long‐lived plasma cells [25]. Therefore, BCMA‐targeted CAR‐T therapy is likely more effective in reducing anti‐HLA antibody levels. However, our study included only one patient who received BCMA CAR‐T cell therapy, and more clinical evidence is needed to substantiate the superiority of BCMA CAR‐T over CD19 CAR‐T in clearing HLA antibodies. Moreover, our recent research indicates that dual‐targeting CD19 and BCMA CAR‐T cells are required to completely eradicate pathogenic antibody‐secreting cells in patients with SLE [26]. Our center is currently conducting a clinical trial on dual‐target CAR‐T therapy for HLA antibody clearance, intending to achieve breakthroughs in this area in the near future. Given the high cost of CAR‐T cell therapy, the risk of severe and potentially life‐threatening toxicities and the unique concern in AML patients that targeting non‐tumour antigens may induce significant toxicity with no direct anti‐leukaemic benefit [15, 16, 17, 18, 19], this therapeutic strategy is likely most clinically appropriate in settings where CAR‐T cells can confer both desensitisation and anti‐tumoural activity. Moreover, researchers are currently developing CAR‐T cells that target specific HLA antibodies (such as HLA‐A02:01 and HLA‐A03:01) [27, 28] to achieve the precise clearance of specific HLA antibodies, which may greatly reduce the occurrence of side effects. In summary, while CD19 CAR‐T cell therapy alone can clear some B cells that secrete anti‐HLA antibodies, its efficacy remains limited. Our study reports a case in which BCMA CAR‐T cell therapy led to a significant decrease in HLA antibodies and DSA, enabling successful allo‐HSCT. These findings suggest that both CD19 and BCMA CAR‐T cell therapies hold potential for anti‐HLA antibody sensitisation. However, given the small sample size, further research with a larger cohort is needed to thoroughly evaluate the effectiveness and safety of CD19/BCMA CAR‐T cells. Author Contributions H.Z., H.Z., Y.H. and H.H. designed the study; H.Z., H.Z., X.Z., S.H., J.C. and S.H. analysed and interpreted the data; H.Z., H.Z., X.Z. and Y.H. drafted the article; J.F. and H.H. revised the article; A.H.C. and Y.Z. helped manufacture CAR‐T cells; S.F., Y.H., M.Z., G.W. and H.H. provided CAR‐T cell treatment and care to the patients; and J.S. and Y.L. provided stem cell transplantation and care to the patients. Funding This work was supported by the National Natural Science Foundation of China (Grant No. 82341206, 82270234 and 82270235), the National Key R&D Program of China (grant no. 2023YFC3403700), the Zhejiang Province's Vanguard Geese Leading Plan Project (2024C3156), the Sanming Project of Medicine in Shenzhen (SZSM202111004) and the Postdoctoral Fellowship Program of the CPSF (grant no. GZB20230643). Conflicts of Interest A.H.C. and Y.Z. were employed by Shanghai Yake Biotechnology Ltd. The authors declare no conflicts of interest. Acknowledgements We thank the staff of Shanghai YaKe Biotechnology Ltd. for their technical support and the nurses at the Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine. Contributor Information Yongxian Hu, Email: 1313016@zju.edu.cn. He Huang, Email: huanghe@zju.edu.cn. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.